T1	Participants 669 787	1397 antiretroviral-treatment-naive patients, presenting at 18 clinical trial units with 80 research sites in the USA,
T2	Participants 1479 1534	1397 patients were assessed for the composite endpoint.
T3	Participants 1546 1638	388 participants developed the composite endpoint, 302 developed AIDS or died, and 188 died.
T4	Participants 3011 3044	treatment-naive patients with HIV